As of Friday close, Atara Biotherapeutics Inc.’s (NASDAQ:ATRA) stock was down -$0.06, moving down -1.38 percent to $4.29. The average number of shares traded per day over the past five days has been 1,632,100 shares. 4 times new highs have been achieved over the past 5 days, with a $0.26 gain in that time frame. In the last twenty days, the average volume was 2,825,675, while in the previous 50 days, it was 2,829,290.
Since last month, ATRA stock rose 26.92%. Shares of the company fell to $3.02 on 08/03/22, the lowest level in the past month. A 52-week high of $20.04 was reached on 01/03/22 after having rallying from a 52-week low of $2.83. Since the beginning of this year, ATRA’s stock price has dropped by -72.78% or -$11.47, and marked a new high 1 time. However, the stock has declined by -78.59% since its 52-week high.
China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal
Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.
Simply click here and the name & trading symbol are yours.
Atara Biotherapeutics Inc. (ATRA) last reported insider trading activity 18 days ago on Aug 16. Touchon Pascal, the President and CEO of the company, disposed of 14,806 shares for $5.04 on Aug 16. It resulted in a $74,548 divestment by the insider. Dupont Jakob sold 4,124 shares at an average price of $5.03 on Aug 16. The insider now owns 158,882 shares following the transaction. On Aug 16, SVP, GC & Secretary Murugan Amar sold 3,430 shares at $5.03 apiece. The transaction was valued at $17,269.
The stock’s beta is 1.10. Besides these, the trailing price-to-sales (P/S) ratio of 6.38, the price-to-book (PB) ratio of 1.70.
In the three months ended June 29, Atara Biotherapeutics Inc.’s quick ratio stood at 5.30, while its current ratio was 5.30, showing that the company is able to pay off its debt. Based on annual data, ATRA earned $360.8 million in gross profit and brought in $20.34 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -121.70%. Return on equity (ROE) for the past 12 months was -92.40%.
According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. ATRA’s revenue rose 92.5% to $7.31 million during the quarter, while net income inched up to $51.58 million. While analysts expected Atara Biotherapeutics Inc. to report -$0.93 quarterly earnings, the actual figure was $0.18 per share, beating the consensus estimate by 119.40%. During the quarter, the company generated -$30.38 million in EBITDA. The liabilities of Atara Biotherapeutics Inc. were 178.64 million at the end of its most recent quarter ended June 29, and its total debt was $74.67 million. The value of shareholders’ equity is $94.36 million.
This quick technical analysis looks at Atara Biotherapeutics Inc.’s (ATRA) price momentum. With a historical volatility rate of 91.19%, the RSI 9-day stood at 49.74% on 02 September.
With respect to its five-day moving average, the current Atara Biotherapeutics Inc. price is up by +6.45% percent or $0.26. At present, ATRA shares trade +24.71% above its 20-day simple moving average and -48.56% percent below its 100-day simple moving average. However, the stock is currently trading approximately -41.63% below its SMA50 and -75.30% below its SMA200.
Stochastic coefficient K was 19.89% and Stochastic coefficient D was 12.81%, while ATR was 0.39. Given the Stochastic reading of 28.97% for the 14-day period, the RSI (14) reading has been calculated as 48.56%. As of today, the MACD Oscillator reading stands at -0.01, while the 14-day reading stands at -0.15.
Atara Biotherapeutics Inc. downgraded its rating on Atara Biotherapeutics Inc. (NASDAQ: ATRA) to a Sell in a note to investors on July 20, 2022. The analysts firm previously had a Neutral rating on the stock.Atara Biotherapeutics Inc. (ATRA) has been rated Overweight by analysts. According to 2 brokerage firms, ATRA is a sell, and 2 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Atara Biotherapeutics Inc. stock as buy, with 6 recommending it as overweight.
With a median target price of $14.65, the current consensus forecast for the stock is $3.00 – $50.00. Based on these forecasts, analysts predict Atara Biotherapeutics Inc. (ATRA) will achieve an average price target of $18.79.